<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02044523</url>
  </required_header>
  <id_info>
    <org_study_id>CE12.062</org_study_id>
    <nct_id>NCT02044523</nct_id>
  </id_info>
  <brief_title>Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound</brief_title>
  <acronym>ELF</acronym>
  <official_title>Comparison of Magnetic Resonance and Ultrasound Elastography With Liver Biopsy for Noninvasive Staging of Liver Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche du Centre Hospitalier de l'Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver fibrosis is an important public health problem, with a substantial morbidity and&#xD;
      mortality due to progression to cirrhosis and hepatocellular carcinoma. All causes of chronic&#xD;
      liver disease may lead to fibrosis. The traditional diagnostic approach requires a biopsy for&#xD;
      assessing the severity of liver disease prior to therapy.&#xD;
&#xD;
      However, liver biopsy has several limitations: cost, sampling error, and procedure-related&#xD;
      morbidity and mortality. Considering the high prevalence of viral hepatitis and nonalcoholic&#xD;
      fatty liver disease, a condition often associated with obesity and type 2 diabetes, there is&#xD;
      an urgent need for noninvasive screening, diagnosis and monitoring strategies of chronic&#xD;
      liver disease severity.&#xD;
&#xD;
      Our team has the expertise to investigate ultrasound-based and magnetic resonance-based&#xD;
      elastographic methods for the noninvasive staging of liver fibrosis.&#xD;
&#xD;
      The primary objective of this cross-sectional study is to compare the sensitivity of&#xD;
      elastographic methods for detecting histology-determined significant fibrosis.&#xD;
&#xD;
      The secondary objectives are to compare the diagnostic accuracy of these elastographic&#xD;
      methods and the influence of potential confounders (inflammation, steatosis and iron&#xD;
      deposition) on their diagnostic accuracy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Liver fibrosis is an important public health problem, with a substantial&#xD;
      morbidity and mortality due to cirrhosis (the end stage) and hepatocellular carcinoma. All&#xD;
      causes of chronic liver disease may lead to fibrosis. The amount of fibrosis determines the&#xD;
      prognosis and influences the response to treatment of chronic liver disease.&#xD;
&#xD;
      Several elastographic methods have been proposed for noninvasive detection and staging of&#xD;
      liver fibrosis. Transient elastography (Fibroscan) is widely used by clinicians. Acoustic&#xD;
      radiation force impulse (ARFI) is an elastography technique recently integrated in clinical&#xD;
      ultrasound systems that may provide similar diagnostic performance to transient elastography.&#xD;
      Magnetic resonance elastography (MRE) is a new method that can be integrated to a liver MRI&#xD;
      study, which would allow liver stiffness, steatosis, iron overload and inflammation&#xD;
      quantification in chronic liver disease.&#xD;
&#xD;
      Objectives: 1) To compare the sensitivity of MRE and ARFI for detecting histology-determined&#xD;
      significant fibrosis (F ≥ 2). Secondary objectives: 2) To compare the diagnostic accuracy of&#xD;
      MRE, ARFI and Fibroscan for predicting histology-determined fibrosis stages. 3) To determine&#xD;
      the influence of inflammation, steatosis, and iron deposition on the diagnostic accuracy of&#xD;
      MRE, ARFI and Fibroscan for predicting fibrosis. 4) To determine thresholds optimizing&#xD;
      sensitivity of ARFI and Fibroscan to screen patients and optimizing specificity of MRE to&#xD;
      confirm liver fibrosis stage.&#xD;
&#xD;
      Design: This will be a cross-sectional imaging trial comparing feasibility, diagnostic and&#xD;
      fibrosis staging accuracy of stiffness measurements by elastographic methods in 108 patients&#xD;
      with chronic liver disease, using histopathology as the reference standard. Paired index&#xD;
      tests (MRE, ARFI and Fibroscan) will be performed as research procedures in close temporal&#xD;
      proximity to the reference test (liver biopsy).&#xD;
&#xD;
      Inclusion criteria: consecutive adult patients with known or suspected chronic liver disease&#xD;
      secondary to hepatitis B virus, hepatitis C virus, or nonalcoholic fatty liver disease&#xD;
      (NAFLD) undergoing a liver biopsy for clinical indications.&#xD;
&#xD;
      Exclusion criteria: any contraindication to MRI, refusal to participate or provide informed&#xD;
      consent, pregnant women, any other cause of chronic liver disease than hepatitis B, hepatitis&#xD;
      C or NAFLD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Histology-determined fibrosis stage</measure>
    <time_frame>Within 6 weeks of elastographic methods</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibroscan-determined liver stiffness</measure>
    <time_frame>Within 6 weeks of liver biopsy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acoustic Radiation Force Impulse (ARFI)-determined liver stiffness</measure>
    <time_frame>Within 6 weeks of liver biopsy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Elastography (MRE)-determined liver stiffness</measure>
    <time_frame>Within 6 weeks of liver biopsy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging (MRI)-based Proton Density Fat Fraction (PDFF)</measure>
    <time_frame>Within 6 weeks of liver biopsy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging (MRI) cine-tagging of cardiac-induced motion for staging liver fibrosis</measure>
    <time_frame>Within 6 weeks of liver biopsy</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">108</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis B</condition>
  <condition>Nonalcoholic Fatty Liver Disease (NAFLD)</condition>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Hepatis C, Hepatitis B, NAFLD</arm_group_label>
    <description>All patients enrolled will undergo:&#xD;
Transient Elastography (Fibroscan)&#xD;
Acoustic Radiation Force Impulse (ARFI)&#xD;
Magnetic Resonance Elastography (MRE)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transient elastography, acoustic radiation force impulse, magnetic resonance elastography</intervention_name>
    <description>Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)</description>
    <arm_group_label>Hepatis C, Hepatitis B, NAFLD</arm_group_label>
    <other_name>Transient elastography (Fibroscan)</other_name>
    <other_name>Acoustic Radiation Force Impulse (ARFI)</other_name>
    <other_name>Magnetic Resonance Elastography (MRE)</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver biopsy specimens.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The target population is adults with any of the three main causes of liver fibrosis: HBV,&#xD;
        HCV or NASH. For the purpose of this study, we will recruit patients seen at the hepatology&#xD;
        clinic of St-Luc Hospital, a tertiary care center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  are adults;&#xD;
&#xD;
          -  must undergo a liver biopsy as part of their clinical standard of care for suspected&#xD;
             or known chronic liver disease caused by HBV, HCV or NASH;&#xD;
&#xD;
          -  understand French or English instruction;&#xD;
&#xD;
          -  Autoimmune Hepatitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have any contra-indication to MRI (such as claustrophobia, pacemaker, metallic clips&#xD;
             for a neurosurgical procedure);&#xD;
&#xD;
          -  are pregnant or trying to become pregnant;&#xD;
&#xD;
          -  have a weight or girth preventing them from entering the MR magnet bore;&#xD;
&#xD;
          -  are unable to understand or unwilling to provide written informed consent for this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>An Tang, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>January 20, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2014</study_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic liver disease</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Elastography</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Magnetic resonance elastography</keyword>
  <keyword>Diagnostic performance</keyword>
  <keyword>Sensitivity and specificity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

